Covered recipient · General Payments record
NAIM ALKHOURI
Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2021 · Entire year
$84,282.13
118 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2021 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $41,550.00 | 21 |
| Consulting Fee | $15,410.00 | 7 |
| Compensation for serving as faculty or as a speaker for a medical education program | $11,070.00 | 4 |
| Travel and Lodging | $7,191.39 | 4 |
| Honoraria | $7,180.00 | 8 |
| Food and Beverage | $1,744.79 | 69 |
| Education | $135.95 | 5 |
By paying entity
PY2021 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $19,298.37 | 37 |
| Intercept Pharmaceuticals, Inc. | $17,448.99 | 15 |
| Echosens North America, Inc. | $13,644.39 | 6 |
| AbbVie Inc. | $11,115.43 | 17 |
| PFIZER INC. | $7,200.00 | 2 |
| Alexion Pharmaceuticals, Inc. | $6,008.83 | 7 |
| Novo Nordisk Inc | $3,418.18 | 7 |
| Theratechnologies Inc. | $3,000.00 | 1 |
| Eisai Inc. | $2,331.87 | 6 |
| Boehringer Ingelheim International GmbH | $600.00 | 1 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $117.46 | 13 |
| Merck Sharp & Dohme Corporation | $55.46 | 3 |
| Alnylam Pharmaceuticals Inc. | $20.17 | 1 |
| BOSTON SCIENTIFIC CORPORATION | $16.11 | 1 |
| Travere Therapeutics, Inc. | $6.87 | 1 |
Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
NAIM ALKHOURI
NPI 1134336662 · CMS profile ID 277931
Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology
WESTLAKE, OH
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1134336662?year=2021&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- NAIM ALKHOURI, NPI 1134336662, CMS profile ID 277931. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1134336662?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- APA 7
- IndustryPayments. (2026). NAIM ALKHOURI, NPI 1134336662, CMS profile ID 277931. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1134336662?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
- Bluebook
- NAIM ALKHOURI, NPI 1134336662, CMS profile ID 277931, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 118 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1134336662?year=2021&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2021
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30
118 matching records · $84,282.13 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 118.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Gilead Sciences, Inc. | $3,000.00 | 07/26/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845851807 | CMS |
| Gilead Sciences, Inc. | $100.27 | 07/26/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154559 | CMS |
| Gilead Sciences, Inc. | $18.88 | 07/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154557 | CMS |
| Boehringer Ingelheim International GmbH | $600.00 | 07/19/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 822296785 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $7.58 | 07/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850168607 | CMS |
| Eisai Inc. | $21.63 | 07/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818057019 | CMS |
| Gilead Sciences, Inc. | $3.87 | 07/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154555 | CMS |
| AbbVie Inc. | $27.62 | 07/01/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793854585 | CMS |
| Eisai Inc. | $23.55 | 06/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833776829 | CMS |
| Gilead Sciences, Inc. | $1,350.00 | 06/30/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845851805 | CMS |
| Gilead Sciences, Inc. | $10.46 | 06/29/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154553 | CMS |
| Alexion Pharmaceuticals, Inc. | $1,000.00 | 06/24/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783109419 | CMS |
| Gilead Sciences, Inc. | $16.68 | 06/23/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154551 | CMS |
| Theratechnologies Inc. | $3,000.00 | 06/22/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 834896465 | CMS |
| AbbVie Inc. | $28.04 | 06/15/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793854581 | CMS |
| Alexion Pharmaceuticals, Inc. | $1,000.00 | 06/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783109421 | CMS |
| Intercept Pharmaceuticals, Inc. | $570.00 | 06/15/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836203105 | CMS |
| Gilead Sciences, Inc. | $3.38 | 06/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154549 | CMS |
| Gilead Sciences, Inc. | $3.35 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154547 | CMS |
| Merck Sharp & Dohme Corporation | $17.19 | 06/09/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848431029 | CMS |
| Novo Nordisk Inc | $2,160.00 | 06/04/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849783117 | CMS |
| AbbVie Inc. | $40.04 | 06/03/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793854577 | CMS |
| Gilead Sciences, Inc. | $95.81 | 06/02/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154545 | CMS |
| Intercept Pharmaceuticals, Inc. | $570.00 | 06/01/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836203103 | CMS |
| Novo Nordisk Inc | $1,080.00 | 06/01/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849786921 | CMS |
| Gilead Sciences, Inc. | $3.80 | 05/25/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154543 | CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $6.50 | 05/20/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 850029211 | CMS |
| Intercept Pharmaceuticals, Inc. | $114.48 | 05/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836203099 | CMS |
| Intercept Pharmaceuticals, Inc. | $3,400.00 | 05/13/2021 | Compensation for serving as faculty or as a speaker for a medical education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836203101 | CMS |
| AbbVie Inc. | $22.58 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793854573 | CMS |
| Gilead Sciences, Inc. | $3.53 | 05/11/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154541 | CMS |
| Gilead Sciences, Inc. | $3.27 | 05/05/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154539 | CMS |
| Gilead Sciences, Inc. | $5.84 | 04/30/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154537 | CMS |
| Novo Nordisk Inc | $32.27 | 04/30/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849783113 | CMS |
| Novo Nordisk Inc | $32.27 | 04/30/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849797893 | CMS |
| Novo Nordisk Inc | $32.27 | 04/30/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849797895 | CMS |
| Novo Nordisk Inc | $32.27 | 04/30/2021 | Education | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 849797897 | CMS |
| Gilead Sciences, Inc. | $2.93 | 04/28/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154535 | CMS |
| Gilead Sciences, Inc. | $2.75 | 04/22/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154533 | CMS |
| Eisai Inc. | $36.68 | 04/16/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833770647 | CMS |
| Gilead Sciences, Inc. | $19.89 | 04/14/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154531 | CMS |
| Gilead Sciences, Inc. | $13.05 | 04/13/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154529 | CMS |
| Eisai Inc. | $30.01 | 04/12/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 818056419 | CMS |
| Alexion Pharmaceuticals, Inc. | $1,000.00 | 04/01/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 783109347 | CMS |
| PFIZER INC. | $1,600.00 | 04/01/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833388247 | CMS |
| Gilead Sciences, Inc. | $3.64 | 03/31/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 848154527 | CMS |
| Intercept Pharmaceuticals, Inc. | $520.00 | 03/25/2021 | Honoraria | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 836203097 | CMS |
| AbbVie Inc. | $29.03 | 03/24/2021 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 793854569 | CMS |
| Eisai Inc. | $1,470.00 | 03/24/2021 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 833763915 | CMS |
| Gilead Sciences, Inc. | $400.00 | 03/15/2021 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 845851803 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $35,289.77 | 37 |
| PY2025 | Principal investigator | $890,501.10 | 106 |
| PY2024 | Recipient | $7,857.76 | 13 |
| PY2024 | Principal investigator | $2,051,472.57 | 233 |
| PY2023 | Principal investigator | $2,475,441.45 | 155 |
| PY2022 | Recipient | $4,281.01 | 6 |
| PY2022 | Principal investigator | $247,137.49 | 39 |
| PY2021 | Recipient | $16,730.00 | 14 |
| PY2021 | Principal investigator | $424,276.54 | 231 |
| PY2020 | Recipient | $330.00 | 1 |
| PY2020 | Principal investigator | $736,691.04 | 49 |
| PY2019 | Recipient | $1,496.76 | 7 |
| PY2019 | Principal investigator | $1,383,155.00 | 59 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
143 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Recipient | Eli Lilly and Company | $915.38 | 12/17/2025 | Covered Recipient Physician | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187872851 |
| Recipient | Eli Lilly and Company | $934.02 | 12/17/2025 | Covered Recipient Physician | A MASTER PROTOCOL FOR A RANDOMIZED, CONTROLLED, CLINICAL TRIAL OF MULTIPLE PHARMACOLOGIC AGENTS IN ADULT PARTICIPANTS WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE WHO ARE AT INCREASED RISK OF DEVELOPING MAJOR ADVERSE LIVER OUTCOMES | No dispute reported | 06/30/2026 | 1187876949 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $6,160.00 | 11/07/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223288109 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $140.00 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167561 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $56.00 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167563 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $77.00 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167565 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $105.00 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167567 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $110.60 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167569 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $121.80 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167571 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $175.00 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167573 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $280.00 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167575 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $420.00 | 10/08/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167577 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $758.70 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184244509 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $12,150.00 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184244511 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $330.00 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184244513 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,064.50 | 10/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184244517 |
| Principal investigator 1 | Gilead Sciences, Inc. | $17,450.00 | 10/01/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206979 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $1,242.25 | 09/11/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167529 |
| Principal investigator 1 | AstraZeneca UK Limited | $36,721.00 | 08/06/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH II LLC | A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA | No dispute reported | 06/30/2026 | 1185542764 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $1,000.00 | 06/27/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167553 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $2,000.00 | 06/27/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167555 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $2,500.00 | 06/27/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167557 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $15,000.00 | 06/27/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167559 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $119.88 | 06/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685075 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $1,058.50 | 06/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685077 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.00 | 06/24/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685079 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,353.39 | 06/12/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248245380 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $2,000.00 | 06/11/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192127894 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $850.00 | 06/11/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192127907 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $500.00 | 06/11/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192127914 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $850.00 | 06/11/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, STUDY TO ASSESS THE EFF | No dispute reported | 06/30/2026 | 1192127921 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,835.68 | 06/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184204463 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $495.00 | 06/05/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184204465 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $52,248.60 | 06/04/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA | No dispute reported | 06/30/2026 | 1185542770 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $16,977.45 | 05/26/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123689 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,609.89 | 05/22/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248244276 |
| Recipient | Boehringer Ingelheim International GmbH | $627.00 | 05/16/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623718 |
| Recipient | Boehringer Ingelheim International GmbH | $18.00 | 05/16/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623728 |
| Recipient | Boehringer Ingelheim International GmbH | $60.00 | 05/16/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623730 |
| Recipient | Boehringer Ingelheim International GmbH | $11.62 | 05/16/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623732 |
| Recipient | Boehringer Ingelheim International GmbH | $47.00 | 05/15/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623722 |
| Recipient | Boehringer Ingelheim International GmbH | $17.00 | 05/15/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623724 |
| Recipient | Boehringer Ingelheim International GmbH | $77.25 | 05/15/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623726 |
| Recipient | Boehringer Ingelheim International GmbH | $7,040.20 | 05/15/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623734 |
| Recipient | Boehringer Ingelheim International GmbH | $71.86 | 05/15/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623736 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,780.13 | 05/15/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248243781 |
| Recipient | Boehringer Ingelheim International GmbH | $80.00 | 05/14/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623720 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 05/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685073 |
| Principal investigator 1 | Eli Lilly and Company | $20,000.00 | 04/30/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH LLC | A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS | No dispute reported | 06/30/2026 | 1187881824 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $9,431.03 | 04/23/2025 | Non-covered Recipient Entity Arizona Liver Health | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545573 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $7,709.25 | 04/23/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184188965 |
| Principal investigator 1 | Gilead Sciences, Inc. | $6,604.00 | 04/22/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | A 52-week, Double-blind, Placebo-controlled, Randomized, Phase 3 Study Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) | No dispute reported | 06/30/2026 | 1229206973 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,154.60 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242044 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $50.00 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242097 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,662.50 | 04/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248242101 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,936.96 | 04/09/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123683 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $55.00 | 04/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685065 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $29.00 | 04/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685067 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $150.00 | 04/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685069 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $28.00 | 04/01/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685071 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,139.50 | 04/01/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184180608 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123664 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123670 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $560.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123677 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $42.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123696 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $420.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123702 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $176.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123714 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $280.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127875 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $490.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127880 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $132.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127900 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127925 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $88.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192129867 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $140.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192179306 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $42.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192179310 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $88.00 | 03/31/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192179314 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685055 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685057 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685059 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685061 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685063 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $151.58 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | -Ph III MASH pivotal trial (MASH F4) | No dispute reported | 06/30/2026 | 1220685081 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $139.86 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | -Ph III MASH pivotal trial (MASH F4) | No dispute reported | 06/30/2026 | 1220685083 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $620.50 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | -Ph III MASH pivotal trial (MASH F4) | No dispute reported | 06/30/2026 | 1220685085 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $39.08 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | -Ph III MASH pivotal trial (MASH F4) | No dispute reported | 06/30/2026 | 1220685087 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.00 | 03/25/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | -Ph III MASH pivotal trial (MASH F4) | No dispute reported | 06/30/2026 | 1220685089 |
| Principal investigator 1 | Grifols Shared Services North America, Inc. | $3,425.00 | 03/25/2025 | Non-covered Recipient Entity The Institute of Liver Health II LLC dba Arizona Clinical Trials | A Randomized, Double-Blind, Placebo-Controlled, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 Administered as a Single Ascending Dose and Multiple Ascending Doses in Participants With Chronic Hepatitis B Virus Infection | No dispute reported | 06/30/2026 | 1244167597 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $12,648.30 | 03/21/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192129860 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,569.75 | 03/19/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184174314 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $2.14 | 03/14/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685039 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $12.86 | 03/14/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685041 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $259.00 | 03/14/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685043 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $5.52 | 03/14/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685045 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $33.71 | 03/14/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685047 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 03/14/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685049 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $4.50 | 03/14/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685051 |
| Principal investigator 1 | Boehringer Ingelheim International GmbH | $21.43 | 03/14/2025 | Non-covered Recipient Entity The Institute for Liver Health II LLC | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220685053 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,139.50 | 03/11/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184170716 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,621.08 | 03/06/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240244 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $6,386.80 | 03/04/2025 | Non-covered Recipient Entity Arizona Liver Health | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545571 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,100.00 | 03/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184156544 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $13,000.00 | 03/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184156546 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,200.00 | 03/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184156548 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $8,066.00 | 03/04/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184156552 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $12,015.00 | 02/27/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248240003 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $4,297.23 | 02/24/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192123708 |
| Principal investigator 1 | Takeda Pharmaceuticals U.S.A., Inc. | $2,659.55 | 02/24/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | THE STUDY EXPLORES THE MECHANISM OF ACTION AND EVALUATES THE SAFETY OF ONTAMALIMAB IN PARTICIPANTS WITH NONALCOHOLIC STEATOHEPATITIS WITH FIBROSIS STAGES 2 THROUGH 4 | No dispute reported | 06/30/2026 | 1223275497 |
| Recipient | Boehringer Ingelheim International GmbH | $7.95 | 02/23/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623770 |
| Recipient | Boehringer Ingelheim International GmbH | $41.10 | 02/23/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623772 |
| Recipient | Boehringer Ingelheim International GmbH | $8.46 | 02/23/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623774 |
| Recipient | Boehringer Ingelheim International GmbH | $41.10 | 02/23/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623776 |
| Recipient | Boehringer Ingelheim International GmbH | $8.46 | 02/23/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623778 |
| Recipient | Boehringer Ingelheim International GmbH | $41.10 | 02/23/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623780 |
| Recipient | Boehringer Ingelheim International GmbH | $8.46 | 02/23/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623782 |
| Recipient | PFIZER INC. | $1,400.00 | 02/22/2025 | Covered Recipient Physician | PF06835919 CLINICAL PUBLICATION PROGRAM | No dispute reported | 06/30/2026 | 1228829613 |
| Principal investigator 1 | AstraZeneca UK Limited | $210,950.90 | 02/21/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A Phase 2a Randomised Single blind Placebo controlled Study to Evaluate the Safety Tolerability and Pharmacokinetics and Explore the Pharmacodynamic Effects of AZD2389 in participants with Liver Fibrosis and Compensated Cirrhosis BORANA | No dispute reported | 06/30/2026 | 1185542766 |
| Recipient | Boehringer Ingelheim International GmbH | $62.00 | 02/21/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623784 |
| Principal investigator 1 | Eli Lilly and Company | $13,900.00 | 02/20/2025 | Non-covered Recipient Entity ARIZONA RESEARCH CENTER | A PARALLEL-GROUP, SINGLE-DOSE, PHASE 1, OPEN-LABEL STUDY TO INVESTIGATE THE PHARMACOKINETICS OF LY3437943 IN PARTICIPANTS WITH HEPATIC IMPAIRMENT COMPARED WITH HEALTHY PARTICIPANTS | No dispute reported | 06/30/2026 | 1187874643 |
| Recipient | Boehringer Ingelheim International GmbH | $1,050.76 | 02/14/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623738 |
| Recipient | Boehringer Ingelheim International GmbH | $87.64 | 02/14/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623740 |
| Recipient | Boehringer Ingelheim International GmbH | $98.59 | 02/14/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623742 |
| Recipient | Boehringer Ingelheim International GmbH | $7,415.41 | 02/12/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623744 |
| Recipient | Boehringer Ingelheim International GmbH | $131.45 | 02/12/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623746 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $9,394.31 | 02/06/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248239081 |
| Recipient | Boehringer Ingelheim International GmbH | $471.21 | 01/31/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623748 |
| Recipient | Boehringer Ingelheim International GmbH | $15.39 | 01/31/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623758 |
| Recipient | Boehringer Ingelheim International GmbH | $47.01 | 01/31/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623760 |
| Recipient | Boehringer Ingelheim International GmbH | $15.39 | 01/31/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623762 |
| Recipient | Boehringer Ingelheim International GmbH | $47.01 | 01/30/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623752 |
| Recipient | Boehringer Ingelheim International GmbH | $15.39 | 01/30/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623754 |
| Recipient | Boehringer Ingelheim International GmbH | $51.31 | 01/30/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623756 |
| Recipient | Boehringer Ingelheim International GmbH | $71.84 | 01/29/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623750 |
| Recipient | Boehringer Ingelheim International GmbH | $14,155.63 | 01/29/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623764 |
| Recipient | Boehringer Ingelheim International GmbH | $48.45 | 01/29/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623766 |
| Recipient | Boehringer Ingelheim International GmbH | $49.33 | 01/29/2025 | Covered Recipient Physician | A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepatitis/metabolic associated steatohepatitis (NASH/MASH) and (F2) - (F3) stage of liver fibrosis | No dispute reported | 06/30/2026 | 1220623768 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $6,431.60 | 01/29/2025 | Non-covered Recipient Entity Arizona Liver Health | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545569 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $17,473.54 | 01/28/2025 | Non-covered Recipient Entity INSTITUTE FOR LIVER HEALTH | 17 B-HYDROXYSTEROID DEHYDROGENASE TYPE 13 MINIMIZATION FOR THE TREATME | No dispute reported | 06/30/2026 | 1192127888 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,537.50 | 01/23/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A 52-WEEK, PHASE 3, OPEN-LABEL EXTENSION STUDY, WITH A DOUBLE-BLIND LEAD-IN, TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM (MGL-3196) IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD), MAESTRO-NAFLD-OPEN-LABEL-EXTENSION (MAESTRO-NAFLD-OLE) | No dispute reported | 06/30/2026 | 1248238732 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $5,139.50 | 01/21/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of siRNA Gene Silencing for the Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Participants With Genetic Risk Factors | No dispute reported | 06/30/2026 | 1184149196 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $2,867.67 | 01/10/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248238378 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $268,873.56 | 01/08/2025 | Non-covered Recipient Entity ARIZONA LIVER HEALTH | A Randomised, Double-blind, Placebo-controlled, Multi-centre Phase 2b Study to Evaluate the Efficacy, Safety and Tolerability of AZD2693 in Participants with Non-cirrhotic Non-alcoholic Steatohepatitis (NASH) with Fibrosis Who Are Carriers of the PNPLA3 rs738409 148M Risk Allele | No dispute reported | 06/30/2026 | 1185542768 |
| Principal investigator 1 | Ipsen Bioscience Inc. | $280.00 | 01/07/2025 | Non-covered Recipient Entity Arizona Liver Health | A Double-blind, Randomized, Placebo-Controlled Study and Open-label Long Term Extension to Evaluate the Efficacy and Safety of Elafibranor 80 mg in Patients With Primary Biliary Cholangitis With Inadequate Response or Intolerance to Ursodeoxycholic Acid | No dispute reported | 06/30/2026 | 1176545567 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $1,823.71 | 01/06/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A 52WEEK PHASE 3 OPENLABEL EXTENSION STUDY WITH A DOUBLEBLIND LEADIN TO EVALUATE SAFETY AND BIOMARKERS OF RESMETIROM MGL3196 IN PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE NAFLD MAESTRONAFLDOPENLABELEXTENSION MAESTRONAFLDOLE | No dispute reported | 06/30/2026 | 1248238067 |
| Principal investigator 1 | Madrigal Pharmaceuticals | $3,009.69 | 01/03/2025 | Non-covered Recipient Entity THE INSTITUTE FOR LIVER HEALTH II LLC | A PHASE 3 MULTINATIONAL DOUBLEBLIND RANDOMIZED PLACEBOCONTROLLED STUDY OF MGL3196 RESMETIROM IN PATIENTS WITH NONALCOHOLIC STEATOHEPATITIS NASH AND FIBROSIS TO RESOLVE NASH AND REDUCE PROGRESSION TO CIRRHOSIS ANDOR HEPATIC DECOMPENSATION | No dispute reported | 06/30/2026 | 1248237923 |